Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

DIAGNOS INC V.ADK

Sector: Technology | Sub-Sector: Software - Application
Alternate Symbol(s):  DGNOF

Diagnos Inc provides data mining & interpretation services to assist exploration companies in identifying mining deposits, health specialists in the detection of diabetic retinopathy, & predict if a song has the potential to become a commercial hit.
Price: $0.09 Volume: 10,000
Change: $0.00 % Change: 0.00%
Day High/Low: 0.09/0.085 52 Week High/Low: 0.11/0.035
Last Traded: July 31, 2015 07:58 Transaction Volume: 2000
Open: 0.085 Previous Close: 0.09
Bid: 0.08 Ask: 0.09
Bid Size: 2000 Ask Size: 45000
Market Cap: 9.6m Shares Out: 106.2m
PE Ratio: N/A Dividend Yield: N/A

Latest Bullboard Posts

  • Doctor's offices a good fit

    0 stars

    This article suggest placing automated screening cameras in doctors offices. Excerpt---- As stated by many experts, regular screening for...

    4.5 stars


  • RE:Annual Report

    0 stars

    The whole world is a market for Diagnos. In addition to Europe and the UAE---to substantially grow our sales and marketing successes in...

    4.5 stars


  • RE:Financing Update

    0 stars

    Nice to have First Republic Capital trying to arrange additional financing for Diagnos. They did PHM (Patient Home Monitoring) which went...

    4.5 stars


  • Annual Report

    0 stars

    From the annual report, it appears more focus will be placed on---For the upcoming year, we intend to continue increasing our presence in...

    4.5 stars


  • RE:RE:RE:India

    0 stars

    $31,087 for India fiscal year ended March 31st. Naysayers would have a field day here after all the years spent and even with Novartis...

    4.5 stars